Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Avenida de Atenas, SN, 28922 Alcorcón, Madrid, Spain.
Anticancer Res. 2009 Nov;29(11):4727-30.
In a recent report it was shown that molecular subgroups of early (pT1) breast tumors belonging exclusively to the most common histological variant, ductal-infiltrating carcinoma, showed significantly different clinical and biological features.
To test in a series of patients with ductal-infiltrating carcinoma encompassing all stages of the disease if the above-mentioned biological differences already detected at the earliest stage are ultimately reflected in survival differences.
All patients with ductal infiltrating carcinoma operated upon at Hospital de Móstoles, Madrid, Spain, between 1997 and 2002 were included into the study, to allow for at least five years of follow-up for survivors. Of 242 studied patients, according to the International Federation of Gynecology and Obstetrics (FIGO) classification, 37.6% were in stage I, 47.2% in stage II, 11.0% in stage III, and 4.2% in stage IV. According to the simplified molecular classification of Carey et al., 116 tumors (47.9%) expressed estrogen receptors, and did not express c-erb-B2 (Luminal A), 67 (27.7%) coexpressed hormone receptors (either estrogen receptors, progesterone receptors or both) and c-erb-B2 (Luminal B), 33 (13.3%) expressed c-erb-B2 in the absence of hormone receptors (HER-2), and 26 (10.7%) neither expressed hormone receptors, nor c-erb-B2 (triple-negative, basal).
In a univariate model, both disease-free survival and overall survival of the patients were significantly associated with stage (p=0.0003; p<0.0001), histological grade (p<0.0001; p<0.0001), lymphatic vascular space invasion (p=0005; p=0.0044), menopausal status (p=0.04; p=0.034) and molecular subgrouping (p=0.037: p=0.01). In a multivariate model, only stage (p=0.013), grade (p<0.0001), and menopausal status (p=0.007) retained their prognostic power for predicting disease-free survival, and just stage (p<0.0001) and grade (p<0.0001) for predicting overall survival. The molecular classification of the tumors almost reached statistical significance for predicting overall survival (p=0.06).
最近的一份报告表明,仅属于最常见组织学变异型——导管浸润性癌的早期(pT1)乳腺肿瘤的分子亚群表现出明显不同的临床和生物学特征。
在一系列患有导管浸润性癌的患者中进行研究,这些患者涵盖了疾病的所有阶段,以检验在最早阶段已经检测到的上述生物学差异是否最终反映在生存差异上。
马德里莫斯托莱斯医院于 1997 年至 2002 年间对所有患有导管浸润性癌的患者进行了研究,以便为幸存者提供至少五年的随访。在 242 名研究患者中,根据国际妇产科联合会(FIGO)分类,37.6%处于 I 期,47.2%处于 II 期,11.0%处于 III 期,4.2%处于 IV 期。根据 Carey 等人的简化分子分类,116 个肿瘤(47.9%)表达雌激素受体,不表达 c-erb-B2(Luminal A),67 个(27.7%)同时表达激素受体(雌激素受体、孕激素受体或两者兼有)和 c-erb-B2(Luminal B),33 个(13.3%)表达 c-erb-B2 而不表达激素受体(HER-2),26 个(10.7%)既不表达激素受体,也不表达 c-erb-B2(三阴性,基底)。
在单变量模型中,患者的无病生存率和总生存率均与分期(p=0.0003;p<0.0001)、组织学分级(p<0.0001;p<0.0001)、淋巴管血管空间侵犯(p=0005;p=0.0044)、绝经状态(p=0.04;p=0.034)和分子亚群(p=0.037;p=0.01)显著相关。在多变量模型中,只有分期(p=0.013)、分级(p<0.0001)和绝经状态(p=0.007)保留了预测无病生存率的预后能力,而仅分期(p<0.0001)和分级(p<0.0001)保留了预测总生存率的预后能力。肿瘤的分子分类几乎达到了预测总生存率的统计学意义(p=0.06)。